Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

JAMA Cardiology

Volumn 1, Issue 2, 2016, Pages 136-145

  Dugani, Sagar B ^a,b   Akinkuolie, Akintunde O ^a   Paynter, Nina ^a   Glynn, Robert J ^a,c   Ridker, Paul M ^a   Mora, Samia ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN TRIGLYCERIDE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EDUCATIONAL STATUS; ETHNICITY; FAMILY HISTORY; FEMALE; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; LIPID ANALYSIS; MALE; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX; SMOKING; SYSTOLIC BLOOD PRESSURE; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; MIDDLE AGED; OUTCOME ASSESSMENT; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

AGED; C-REACTIVE PROTEIN; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK FACTORS; ROSUVASTATIN CALCIUM; TRIGLYCERIDES;

EID: 85024849868     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.0096     Document Type: Article

References (35)

1. Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753):1670-1681.
2. Ridker PM, Danielson E, Fonseca FAH, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21): 2195-2207.
3. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013; 1: CD004816.
4. Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-2564.
5. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716):735-742.
6. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013; 346:f2610.
7. Dormuth CR, Filion KB, Paterson JM, et al.; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014; 348: g3244.
8. Waters DD, Ho JE, De Micco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol. 2011; 57(14):1535-1545.
9. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012; 380(9841): 565-571.
10. Hu FB, Manson JE, Stampfer MJ, et al. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med. 2001; 345(11):790-797.
11. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63(25, pt B):2889-2934.
12. Garvey WT, Kwon S, Zheng D, et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003; 52(2):453-462.
13. Festa A, Williams K, Hanley AJG, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study. Circulation. 2005; 111(25): 3465-3472.
14. Goff DC Jr, D'Agostino RB Jr, Haffner SM, Otvos JD. Insulin resistance and adiposity influence lipoprotein size and subclass concentrations: results from the Insulin Resistance Atherosclerosis Study. Metabolism. 2005; 54(2):264-270.
15. Hodge AM, Jenkins AJ, English DR, O'Dea K, Giles GG. NMR-determined lipoprotein subclass profile predicts type 2 diabetes. Diabetes Res Clin Pract. 2009; 83(1):132-139.
16. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. Diabetes. 2010; 59(5):1153-1160.
17. Ai M, Otokozawa S, Asztalos BF, et al. Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levels. Am J Cardiol. 2008; 101(3):315-318.
18. Wang J, Stançáková A, Soininen P, et al. Lipoprotein subclass profiles in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med. 2012; 272(6):562-572.
19. Mackey RH, Mora S, Bertoni AG, et al. Lipoprotein particles and incident type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis. Diabetes Care. 2015; 38(4):628-636.
20. Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. Metab Syndr Relat Disord. 2014; 12(8): 422-429.
21. Ridker PM, Fonseca FAH, Genest J, et al.; JUPITER Trial Study Group. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007; 100(11):1659-1664.
22. clinicaltrials.gov. JUPITER-Crestor 20 mg Versus Placebo in Prevention of Cardiovascular (CV) Events. NCT00239681. https://clinicaltrials.gov/ct2/show/NCT00239681. Accessed March 4, 2016.
23. Mora S, Glynn RJ, Boekholdt SM, Nordestgaard BG, Kastelein JJP, Ridker PM. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2012; 59(17):1521-1528.
24. Mora S, Glynn RJ, Ridker PM. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013; 128(11):1189-1197.
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502.
26. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med. 2006; 26(4):847-870.
27. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996; 15(4):361-387.
28. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27(2): 157-172.
29. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011; 30(1):11-21.
30. Preiss D, Sattar N. Statins and the risk of new-onset diabetes: a review of recent evidence. Curr Opin Lipidol. 2011; 22(6):460-466.
31. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al.; DIAGRAM Consortium; MAGIC Consortium; InterAct Consortium. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015; 385(9965):351-361.
32. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010; 55(12): 1209-1216.
33. Koh KK, Quon MJ, Sakuma I, et al. Effects of simvastatin therapy on circulating adipocytokines in patients with hypercholesterolemia. Int J Cardiol. 2011; 146(3):434-437.
34. Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006; 49(8):1881-1892.
35. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol. 2011; 26(4):342-347.